Phase 3 Prostate Cancer Trial, Recruiting NCT03495427 Sponsor: H. Lee Moffitt Cancer Center and Research Institute Condition: Prostate Cancer
Back to Prostate Cancer

Phase 3 Prostate Cancer Trial, Recruiting

NCT03495427
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You must have previously taken part in a specific earlier study called "VANDAAM" (study MCC#18523)
  • Your genetic test result from that earlier study (called a Decipher score) must have come back as high-risk, meaning a score above 0.45
  • You must have had your genetic test successfully completed on a tissue sample taken during a biopsy or surgery
  • You must be generally healthy and able to carry out daily activities with little or no difficulty (confirm with trial site)
  • You must have been treated for prostate cancer with either surgery to remove the prostate, or radiation therapy, with or without a short course of hormone therapy
  • At least 2 years must have passed since you completed your prostate cancer treatment
  • You must be 18 years of age or older

Who may not be able to join:

  • You may not be able to join if there is no medical follow-up information available about your health after your prostate cancer treatment
  • You may not be able to join if you are unable to have a PET scan (a type of medical imaging) due to other existing health conditions or if you experience severe claustrophobia (fear of enclosed spaces)
  • You may not be able to join if you have recently received certain medical substances, including a radioactive medication within a specific time window, an injected dye used in X-rays within the last 24 hours, or a certain type of thick oral contrast drink within the last 5 days (confirm exact timing with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 22 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Kosj Yamoah, M.D., Ph.D., H. Lee Moffitt Cancer Center and Research Institute

Phone: 813-799-6821

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Registry
ClinicalTrials.gov
Start date
18 December 2019
Est. completion
1 February 2029

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Concordance (AUC) Between High Tumor GC Risk Score and Positive PSMA-PET Imaging Findings

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov